

# CORNELL CHRONICLE

June 27, 2017

[Science, Tech & Medicine](#)
[Arts & Humanities](#)
[Business, Law & Society](#)
[Campus Life](#)
[Global Outreach](#)
[Archive](#)

June 27, 2017

## New discovery holds potential as tuberculosis drug

By Lauren Roberts

Brian VanderVen, assistant professor of microbiology and immunology, and colleagues at Cornell's College of Veterinary Medicine, have discovered a key metabolic mechanism in *Mycobacterium tuberculosis* (Mtb) bacteria, which presents as a novel drug target for potentially treating tuberculosis. The finding is published in the journal *eLife*.


Mtb, which currently infects nearly 1.5 billion people and causes more than 1 million deaths each year, requires host lipids (cholesterol and fatty acids) to maintain infection. This is considered a defining characteristic of this pathogen, and is thought to support the bacterium's ability to persist for long periods of time in hosts during both latent and active infections.

However, the mechanisms of how Mtb assimilates the host's fatty acids has remained a mystery – until now.

Using a genetic screen, VanderVen and his team identified genes involved in cholesterol metabolism. This identified the gene *luca*, which encodes a protein of unknown function. To tease out what the protein does, VanderVen's team created a novel  $\Delta$ *luca* Mtb mutant, which revealed that the protein encoded by the gene, *LucA*, is an integral membrane protein, and is required for fatty acid and cholesterol uptake in Mtb. Further work determined that *LucA* interacts with subunits of specific proteins in the *Mce1* and *Mce4* complexes, which import fatty acids and cholesterol, respectively. Specifically, *LucA* stabilizes the transporters – acting as an integral linchpin that, if removed, causes *Mce1* and *Mce4* to fall apart. VanderVen and his research group plan to investigate two other transporters in Mtb – *Mce2* and *Mce3* – using this same approach.

“Our data highlights the complexities and weaknesses of a highly successful intracellular pathogen,” said VanderVen. The discovery sheds new light on how Mtb metabolizes fatty acids and cholesterol, and also firmly establishes that *LucA* is required for full virulence of Mtb in vivo, “and is therefore is a novel drug target in Mtb,” said VanderVen.

The next step for VanderVen and his team will be to investigate drugs that inhibit *LucA*. “This is ideal, because *LucA* is a bottleneck and inhibiting this protein with a chemical could disable two pathways at a time,” said VanderVen. As it happens, “we already have discovered chemicals that do just that, so the next step will be to begin refining these as potential therapeutics.”



Evgeniya Nazarova/Provided  
Macrophages infected with *M. tuberculosis* lipids.

[Bookmarks](#)

### TRENDING

EDITOR'S PICKS	MOST EMAILED	MOST READ
----------------	--------------	-----------

CIS researchers receive \$2.5M NSF grant for cybersecurity

N.Y. honeybees stung hard by varroa mite, researchers find

Cornell to team with IBM to protect global milk supply

Resort legend, Lyft founder honored with Hotel School awards

### SHARE

[Facebook](#)
[LinkedIn](#)
[Reddit](#)
[StumbleUpon](#)
[Twitter](#)
[G+1](#) 0

[Printer-friendly version](#)
[Send by email](#)
[Bookmark](#)

### STORY CONTACTS

#### Cornell Chronicle

George Lowery  
607-255-2171  
[gpl5@cornell.edu](mailto:gpl5@cornell.edu)

#### Media Contact

Melissa Osgood  
607-255-9451  
[mmo59@cornell.edu](mailto:mno59@cornell.edu)

6/27/2017

New discovery holds potential as tuberculosis drug | Cornell Chronicle

*Lauren Roberts is assistant director of communications at the College of Veterinary Medicine and editor of Scopes magazine.*

[About the Office](#)   [Contact Us](#)

Cornell Chronicle • 312 College Ave., Ithaca, NY 14850 • 607-255-4206 ©2017